The combined analysis showed that there is a certain positive correlation between high serum IGF-I levels and prostate cancer risk, but meta-regression did not observe a clear dose-response relationship; that is, elevated IGF-I levels do not necessarily present a “gradient” phenomenon in which the risk increases linearly. The gene discussed is IGF1; the disease is prostate cancer.